After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week.
Discover why Recursion Pharmaceuticals, Inc. stands out in AI drug discovery, but faces valuation risks. Click for my look at ...
When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. The opportunity to explore a multi-genre universe in innovative ways is extremely exciting. Matt ...
In recent developments, Recursion Pharmaceuticals unveiled advances in its AI platform for drug discovery, forming collaborations with major pharmaceutical groups including Sanofi, Roche/Genentech, ...
6don MSN
Forget Recursion Pharmaceuticals: This Could Be an Even Better Artificial Intelligence (AI) Stock
Recursion Pharmaceuticals (NASDAQ: RXRX) has been a pioneer in using artificial intelligence (AI) to improve the drug ...
This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in ...
Recursion Pharmaceuticals RXRX shares have plunged 21.6% so far in May. This considerable decline in the stock was observed after the company reported weaker-than-expected first-quarter 2025 results, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback